Wegovy Cost Statistics 2026 US: Prices and Coverage

What you may actually pay

NovoCare lists Wegovy at $1,349.02 per package for the pill, standard injection pen, and Wegovy HD pen. That is the manufacturer list price before plan rules, rebates, copays, or savings offers. It should not be treated as a dependable estimate of what a pharmacy will charge you. For an uninsured person using the published self-pay route, the standard injection offer is $199 monthly for the first two specified 0.25 mg or 0.5 mg fills for new participants, then $349 monthly for listed standard injection doses. If $349 stayed unchanged for a year, it would be $4,188. That multiplication is a planning example, not a promise that the offer will continue. Wegovy HD is listed at $399 monthly after its introductory period, or $600 more over twelve months than $349 monthly. The daily pill is listed at $149 monthly for 1.5 mg and 4 mg under stated terms. NovoCare says the 4 mg $149 offer ends August 31, 2026, after which the stated amount is $199 monthly unless the program changes.

Coverage and Medicare access

With commercial insurance, the practical question is whether your plan covers Wegovy for your diagnosis and whether it requires prior authorization. Prior authorization means the prescriber's office sends clinical information to the insurer before the plan will pay. NovoCare says many plans require it and that a request can take up to 10 business days. The advertised commercial savings offer says eligible people may pay as little as $25 monthly. That phrase is a floor, not a standard copay. The offer has a $100 monthly maximum savings limit and excludes government beneficiaries. Medicare works differently. Wegovy can be covered through normal Medicare Part D for certain FDA-approved uses, including cardiovascular-risk reduction in qualifying adults with established cardiovascular disease and overweight or obesity. The Medicare GLP-1 Bridge is a separate temporary route for eligible Part D beneficiaries, with a $50 monthly copay through December 31, 2027. CMS says Bridge payments operate outside ordinary Part D payment and deductible rules. The $50 does not count toward the Part D deductible or true out-of-pocket spending threshold. Medicaid coverage varies by state and managed-care plan, so a state plan or insurer must confirm the actual benefit.

What the trial results can mean

Glucagon-like peptide-1, or GLP-1, medicines act on a hormone pathway involved in appetite and blood sugar. Wegovy contains semaglutide. In STEP 1, a 68-week trial of adults with overweight or obesity without diabetes, people using weekly 2.4 mg Wegovy with lifestyle support lost 14.9% of starting body weight on average, compared with 2.4% with placebo. For someone starting at 235 pounds, 14.9% is about 35 pounds on average over roughly a year and four months. It cannot predict one person's result. Cost, side effects, other health conditions, supply, and insurance changes can all affect whether someone stays on treatment. In a trial involving people with type 2 diabetes, average loss with 2.4 mg was 9.6% at 68 weeks, versus 3.4% with placebo. Comparing these groups matters because diabetes status can change trial averages. Wegovy HD is a 7.2 mg weekly injection approved in March 2026. In adults with obesity without type 2 diabetes, the FDA label reports 18.8% average loss at 72 weeks with 7.2 mg, compared with 15.5% with 2.4 mg in the same study. That 3.3-percentage-point difference is meaningful at a population level, but it does not settle what is tolerable, covered, or appropriate for a particular person.

Maintenance and stopping

Cost decisions should include what may happen if treatment stops. In a follow-up study after semaglutide withdrawal, participants regained about two-thirds of their earlier weight loss within one year on average. Regain is common and is not a personal failure. Before starting or restarting, it is reasonable to ask how long coverage is approved for, what happens when a savings offer expires, and what the plan would be if you stop. Those questions matter as much as the first-month quote. A clinician can discuss medical options, while a pharmacist can help clarify the presentation, refill timing, and interactions.

Safety and daily routine

The current label includes a once-weekly injection and a once-daily oral tablet. The injection is used once weekly on the same day each week, with or without meals. The tablet is taken once daily on an empty stomach with water, followed by at least 30 minutes before food, other drinks, or oral medicines; ask a clinician or pharmacist for instructions for the formulation prescribed to you. Common adverse reactions in the label include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, and dizziness. The label also warns about pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, low blood sugar with insulin or certain diabetes medicines, allergic reactions, and some eye risks for people with type 2 diabetes. Wegovy is not a substitute for urgent care. Ask the prescribing team what symptoms should prompt a call, urgent care, or emergency care based on your health history. Also ask for a review of your other medicines because semaglutide can delay stomach emptying.

Dates that can change your options

The March 2024 cardiovascular indication matters because it may affect access through Medicare Part D for qualifying people. In March 2026, FDA approved Wegovy HD. The June 2026 label revision includes injection, pill, and HD presentations. The Medicare GLP-1 Bridge began July 1, 2026. Its scheduled end is December 31, 2027. Manufacturer offer deadlines are nearer: the stated 4 mg tablet $149 offer ends August 31, 2026, and the two-fill $199 injection introductory offer has a stated deadline of December 31, 2026.

Questions to take to a clinician or pharmacist

Ask what FDA-approved reason Wegovy is being prescribed for in your case and whether your plan covers that use. Ask who submits prior authorization, how you will learn the decision, what documentation is needed, and when approval must be renewed. Ask the pharmacy what you will pay after deductible, copay, coinsurance, and any savings offer. Ask which presentation was prescribed, whether your current medicines need review, and what plan makes sense if you cannot tolerate treatment, lose coverage, or decide to stop. Avoid assuming compounded semaglutide is the same as FDA-approved Wegovy. FDA says compounded drugs are not FDA approved and reports concerns about dosing errors, salt forms, and adverse events. FDA had received 990 adverse-event reports associated with compounded semaglutide as of May 31, 2026; reports do not prove causation for every event.